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Scientific Abstracts (IQR 3.75, 4) . Other than 1 Filipino 2 year old girl (patient C), all other infants were of Chinese Singaporean origin and were less than age 1 year at onset; 4 male and 1 female. All patients were found to have multiple areas of irregular, thickened vessel walls with enhancement, involving the aorta and additional medium sized arteries on Magnetic Resonance Angiography (MRA).
Only patients C and F presented with prolonged fever and or less than 1 clinical feature of KD. C developed a unilateral enlarged lymph node on recrudescence of fever 1 month after the initial event. She was then found to have dilated CA (dCA) and consequently abnormal MRA. 
Conclusions:
Extensive involvement of the systemic arteries and aorta in all patient were noted on initial MRA. Follow up imaging, showed improvement in all vessels. After 1 year of follow up, complete resolution occurred only in medium vessels. Mortality in this patient cohort was 2/7 (28.6%). This is an observational case series and our findings will need to be reproduced in larger groups of patients. 
Structural damage and history of articular prosthesis was more common in female ns-JIA patients receiving biological therapy. Functional disability and disease activity were also higher in female patients. On the other hand, the follow-up ns-JIA patients had a good level of remission and low disease activity.The shorter duration until the time of biological treatment in patients diagnosed after 2003 indicates that both pediatric and adult rheumatologists have begun to treat these patients more effectively. Background: Juvenile idiopathic arthritis (JIA) is a chronic arthritis with an onset before 16 years of age, that persists for at least 6 weeks, and has an unknown etiology. 1 Uveitis is a serious and common extra-articular manifestation of JIA, affecting 12-30% of patients (most commonly female with ANA+ oligoarthritis JIA category).
2,3 JIA-associated uveitis can be treated with biologic disease modifying antirheumatic drugs (bDMARDs), including TNF inhibitors (TNFi) such as etanercept (ETN), infliximab (IFX), and adalimumab (ADA), after failure of first-line treatments, such as topical corticosteroids and/or conventional synthetic DMARDs (csDMARDs), such as methotrexate (MTX). 2 Of note, reports exist that ETN use has been associated with uveitis flares or new-onset uveitis while an observational study reported similar uveitis flare rates for both ADA and ETN. 4, 5 Objectives: To conduct an analysis on the occurrence of uveitis in patients with JIA treated with ETN, ADA, or MTX. Combination therapy of ETN, ADA, and MTX was also assessed. Methods: International Statistical Classification of Diseases (ICD)-9 diagnosis codes in a Truven MarketScan ® claims database were used to identify JIA patients diagnosed with uveitis over a 5-year interval. The analysis assessed the proportion of JIA patients (aged 0-19 years) treated with ETN, ADA, or MTX, as monotherapy or in combination. The percentage of patients diagnosed with uveitis and the time interval for uveitis diagnosis in patients with JIA was determined. Results: A total of 22,789 patients with JIA where included in this analysis and exhibited a mean age of 11.4 years, were predominantly female (69%), and mean JIA disease duration was 3 years. This total included 19,814 patients with chronic, or not otherwise specified, polyarticular JIA. A total of 2581 (11.3%) patients, of mean age 10.2 years, of which 73% were female, were diagnosed with uveitis. The numbers of JIA patients receiving biologic and/or MTX therapy and proportions with a uveitis diagnoses are shown in the Figure. Conclusions: This analysis showed a similar occurrence of uveitis in JIA patients treated with ETN or ADA, either as monotherapy or in combination with MTX.
